Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months. Treatment options for these patients remain limited. Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumours and MAPK reactivation occurred in 9/10 tumours, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In cell lines and xenografts, intrinsic and acquired resistance to signaling pathway inhibitors against estrogen, RAF, EGFR, PI3K, and others is sometimes associated with mutations in p16Ink4a, upregulated expression of cyclin D1 or other D-type cyclins, or upregulation of CDK4 or CDK6 (Jiang et al., 2016; Long et al., 2014; Yadav et al., 2014).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Long et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cited by
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Self-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“458 While the activation of the PI3K/AKT pathway does not limit patient responses to BRAF/MEK inhibition, a small subset of resistant melanoma relies on the compensatory PI3K/AKT signaling cascade.”
BackgroundTargeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
“Vemurafenib Selective BRAF V600E inhibitor (ATP competitive) Activating mutations in NRAS or MEK [23,24]; BRAF/CRAF amplification [23,25]; BRAF alternative splicing [26,27]; RAF heterodimerization [28]; RTK upregulation [29]; Loss of NF1 [30]; COT upregulation [31] Dabrafenib”
BackgroundToward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
“REAGENT or RESOURCE SOURCE IDENTIFIER MM087 Prof. G. Ghanem, LOCE-institut J. Bordet, Université Libre de Bruxelles N/A MM162 Prof. G. Ghanem, LOCE-institut J. Bordet, Université Libre de Bruxelles N/A MM032 Prof. G. Ghanem, LOCE-institut J. Bordet, Université Libre de Bruxelles N/A MM031 Prof. G. Ghanem, LOCE-inst…”
InfluentialCombenefit: an interactive platform for the analysis and visualization of drug combinations
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
“…the double-drug approach commonly fails due to acquired resistance (Larkin et al., 2014; Long et al., 2014b) caused by a similar set of mutant genes responsible for acquired resistance to BRAFi monotherapy (Long et al., 2014a; Moriceau et al., 2015; Villanueva et al., 2013; Wagle et al., 2014).”
BackgroundMethodInfluentialRelapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3333 · Cited by 540
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
“Sex, n (%) Male 83 (61) Female 52 (39) ECOG performance status, n (%) 0 45 (33) 1 90 (67)”
BackgroundCheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
“IC50(nM) by cell free assay CDK family kinase complex Palbociclib Ribociclib Abemaciclib CDK4/CyclinD1 11 8 2 CDK4/CyclinD3 9 NR NR CDK6/CyclinD1 NR NR 9.9 CDK6/CyclinD2 15 NR NR CDK6/CyclinD3 NR 39 NR CDK1/CyclinB >10 µM >1.5 µM 1,627 CDK2/CyclinA >10 µM >1.5 µM NR CDK2/CyclinE2 >10 µM >1.5 µM 504 CDK5/p25 >10 µM >1.…”
BackgroundInfluentialGray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H. J., Scolyer, R. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5788 · Cited by 336
“Mutations in NRAS have been found in 8-26% of patients with acquired resistance to BRAF inhibitors [11, 13].”
BackgroundSelf-citationCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316
Amaria, R. N., Prieto, P. A., Tetzlaff, M. T., Reuben, A., Andrews, M. C., Ross, M. I., Glitza, I. C., Cormier, J., Hwu, W.-J., Tawbi, H. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30015-9 · Cited by 299
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., Sosman, J. A., Hamid, O., Schuchter, L., Cebon, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9345 · Cited by 285
Self-citationTargeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
“However, resistance remains a vexing problem [41].”
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
“Nevertheless, EGFR, ERBB3, and AKT also display increased expression and/or phosphorylation in the majority of progressed melanomas (Abel et al., 2013; Girotti et al., 2013; Long et al., 2014).”
BackgroundResultRegulation of autophagy by canonical and non-canonical ER stress responses
Bhardwaj, M., Leli, N. M., Koumenis, C., & Amaravadi, R. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.007 · Cited by 244
Germann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M., Boucher, D. M., Sorrell, D. A., Martinez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 233
“Resistance mechanisms in the setting of BRAF/MEK inhibitor combination therapy are beginning to emerge and mirror that of BRAF single-agent resistance (21, 22).”
BackgroundWaarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 230
“However, in some tumors, even with combined RAF/MEK inhibition, resistance occurs with sustained dependence on MAPK signaling, indicating that combination therapy may still be ineffective at achieving full inhibition (70).”
BackgroundThe influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 223
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
“MEK1C121S has been reported in BRAFV600E-mutated metastatic melanoma with acquired resistance to BRAF inhibition by vemurafenib(24) and, in in vitro models of BRAFV600E melanoma, confers resistance to treatment with the MEK inhibitor selumetinib(24) but not to the combination of dual BRAF and MEK inhibition(25).”
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 217
Self-citationTargeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Atg7 Overcomes Senescence and Promotes Growth of Braf V600E-Driven Melanoma
Xie, X., Koh, J. Y., Price, S., White, E., & Mehnert, J. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1473 · Cited by 208
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
“Patients treated with dabrafenib/trametinib combination therapy developed alterations in the same genes that support single-agent resistance including MEK1/2 mutations, BRAF amplification, BRAF alternative splicing, and NRAS mutations between pretreatment and post-progression samples (8, 9).”
BackgroundCirenajwis, H., Ekedahl, H., Lauss, M., Harbst, K., Carneiro, A., Enoksson, J., Rosengren, F., Werner-Hartman, L., Törngren, T., Kvist, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3655 · Cited by 192
“The gene expression phenotypes and their clinical relevance were Oncotarget12307www.impactjournals.com/oncotarget evaluated in three independent external datasets obtained from GEO (GSE50509 [16]; GSE61992 [17]; GSE35640 [14]).”
InfluentialTargeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Bell, C. C., Fennell, K. A., Chan, Y.-C., Rambow, F., Yeung, M. M., Vassiliadis, D., Lara, L., Yeh, P., Martelotto, L. G., Rogiers, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10652-9 · Cited by 183
Current Advances in the Treatment of BRAF-Mutant Melanoma
Patel, H., Yacoub, N., Mishra, R., White, A., Yuan, L., Alanazi, S., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12020482 · Cited by 174
“Acquired resistance to combination targeted therapy has other factors contributing to it, including whether the patient had received inhibitor monotherapy prior to the combination therapy or is ‘monotherapy naïve’ [62].”
BackgroundPAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents
Peluso, I., Yarla, N. S., Ambra, R., Pastore, G., & Perry, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.002 · Cited by 159
“[55, 56], as well as for the clinical resistance to BRAF/MEK inhibition [57, 58] and it has been suggested that the inhibition of MAPKs, such as ERK [57, 59] or JNK [60] could overcome this problem.”
BackgroundBrady, D. C., Crowe, M. S., Greenberg, D. N., & Counter, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1190 · Cited by 173
“As such, TTM enhanced the antineoplastic activity of BRAFi and MEKi in A375 cells, including in settings of resistance to these inhibitors.”
InfluentialOrgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
“We next validated our findings in clinical samples from published datasets (Hugo et al., 2015; Kakavand et al., 2017; Kwong et al., 2015; Long et al., 2014a; Rizos et al., 2014; Song et al., 2017; Sun et al., 2014; Wagle et al., 2014) (Table S4).”
BackgroundResultCOSMIC: High‐Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Beare, D., Bindal, N., Bamford, S., Ward, S., Cole, C. G., Jia, M., Kok, C., Boutselakis, H., De, T., et al. (2016) · Current Protocols in Human Genetics · doi:10.1002/cphg.21 · Cited by 149
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., Mangino, G., et al. (2020) · Cancers · doi:10.3390/cancers12102801 · Cited by 145
“MEK1/2 mutations [21,44,51,61,62,64] MEK1/2 mutations could reactivate downstream ERK signaling without the need for BRAF stimulation”
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Van Raemdonck, N., Pedri, D., Swings, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.015 · Cited by 141
Self-citationBRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“…is sufficient to confer resistance to BRAF-targeted therapy has been debated and probably differs as a function of the specific MEK variant that is present, with those mutants exhibiting RAF independence being most likely to confer high levels of resistance to RAF inhibitors 99,188,189,193–200 .”
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang-Gillam, A., & Cox, A. D. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 131
“Although combining RAF and MEK inhibitors has shown greater clinical efficacy in BRAFmutant melanoma cancers than either drug alone, reactivation of ERK signaling limits the long-term effectiveness of this combination[72,29].”
BackgroundZEB 1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
Richard, G., Dalle, S., Monet, M., Ligier, M., Boespflug, A., Pommier, R. M., de la Fouchardière, A., Perier‐Muzet, M., Depaepe, L., Barnault, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505971 · Cited by 130
“However, combination therapy does not prevent the appearance of acquired resistance (Flaherty et al, 2012), through genetic mechanisms resembling those described during monotherapy (Long et al, 2014; Moriceau et al, 2015).”
BackgroundA renewed concept on the MAPK signaling pathway in cancers: Polyphenols as a choice of therapeutics
Anjum, J., Mitra, S., Das, R. C., Alam, R., Mojumder, A., Emran, T. B., Islam, F., Rauf, A., Hossain, M. J., Aljohani, A. S. M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106398 · Cited by 135
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 140
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicinska, E., Sulahian, R., Goodale, A., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 128
“The majority of acquired resistance mechanisms to MAPK pathway inhibitor therapy that have been identified in patients with RAF-mutant cancers involve upregulation of MAPK pathway signaling upstream of ERK (Long et al., 2014; Rizos et al., 2014; Shi et al., 2014; Van Allen et al., 2014; Wagle et al., 2011; 2014).”
BackgroundMethodInfluentialMetastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 142
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 123
“At the level of the RAF kinases, CRAF overexpression, BRAF gene amplification and the presence of BRAF truncations (as a consequence of alternative splicing) permit maintenance of ERK activation (50,51), while downstream of BRAF, overexpression or mutation of MEK itself or its activators, COT/TPL2/MAP3K8 or MLKs, have…”
BackgroundTERT promoter mutations in melanoma survival
Nagore, E., Heidenreich, B., Rachakonda, S., Garcia‐Casado, Z., Requena, C., Soriano, V., Frank, C., Traves, V., Quecedo, E., Sanjuan‐Gimenez, J., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30042 · Cited by 119
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Wong, S. Q., Raleigh, J. M., Callahan, J., Vergara, I. A., Ftouni, S., Hatzimihalis, A., Colebatch, A. J., Li, J., Semple, T., Doig, K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00009 · Cited by 112
“Although the MAP2K1 E203K mutation was a likely cause for resistance in this individual, PTEN mutations also have been associated with diminished response to MAPKi therapy and may have contributed to the rapid emergence of the therapeutic resistance observed.(26) In patient MEL-7, TA sequencing and dPCR showed that ch…”
BackgroundBhagwat, S. V., McMillen, W. T., Cai, S., Zhao, B., Whitesell, M., Shen, W., Kindler, L., Flack, R. S., Wu, W., Anderson, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0183 · Cited by 107
“ERK reactivation is common to these mechanisms of acquired resistance leading to rapid recovery of ERK pathway resulting in resistance to single-agent BRAF inhibitor or combination of BRAF/MEK inhibitor therapies (18, 19).”
BackgroundmiR-579-3p controls melanoma progression and resistance to target therapy
Fattore, L., Mancini, R., Acunzo, M., Romano, G., Laganà, A., Pisanu, M. E., Malpicci, D., Madonna, G., Mallardo, D., Capone, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607753113 · Cited by 123
“Moreover, early adaptive responses limit the initial efficacy, leading to incomplete responses and favor the selection of a subpopulation of resistant clones, which ultimately cause disease progression (14, 15).”
BackgroundWnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights
Xue, G., Romano, E., Massi, D., & Mandalà, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.009 · Cited by 120
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 110
“Given the dependency of BRAF-mutant melanomasonMAPKactivity (Long et al., 2014), it seems likely that the presence of the latent physiological configuration represents a key limitation in RAF/MEK therapy.”
BackgroundBRAF Gene and Melanoma: Back to the Future
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 131
“BRAF amplification and NRAS and MEK2 activating mutations are the most frequently observed in both preclinical and clinical settings [93,94].”
BackgroundIrvine, M., Stewart, A., Pedersen, B., Boyd, S., Kefford, R., & Rizos, H. (2018) · Oncogenesis · doi:10.1038/s41389-018-0081-3 · Cited by 107
Self-citationOstrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
Zhang, Y., Chen, H.-X., Zhou, S., Wang, S., Zheng, K., Xu, D., Liu, Y., Wang, X., Wang, X., Yan, H., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0326-0 · Cited by 110
“The MAPK signal pathway (ERK, JNK, p38) is involved in regulating cell growth, differentiation, environmental adaptation to stress, inflammatory reactions, and participated in cancer progression [40].”
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 116
Facchinetti, F., Lacroix, L., Mezquita, L., Scoazec, J.-Y., Loriot, Y., Tselikas, L., Gazzah, A., Rouleau, E., Adam, J., Michiels, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.025 · Cited by 96
Young, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J.-C., Kamarashev, J., Frederick, D. T., Cooper, Z. A., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160855 · Cited by 95
“Such adaptive responses can occur in a cancer cell–autonomous fashion (Johannessen et al., 2010; Nazarian et al., 2010; Villanueva et al., 2010; Poulikakos et al., 2011; Smith et al., 2013; Long et al., 2014).”
BackgroundStrub, T., Ghiraldini, F. G., Carcamo, S., Li, M., Wroblewska, A., Singh, R., Goldberg, M. S., Hasson, D., Wang, Z., Gallagher, S. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05966-z · Cited by 93
Self-citationPD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 91
“We also explored whether resistance effectors were associated with specific profiles of immune cell activity and infiltration derived from previous work (4, 8).”
MethodSelf-citationER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., Rebecca, V. W., Chude, C. I., Murugan, S., Fennelly, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0348 · Cited by 91
TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination
Zhu, G., Herlyn, M., & Yang, X. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00732-8 · Cited by 90
Song, K., Minami, J. K., Huang, A. J. Y., Dehkordi, S. R., Lomeli, S. H., Luebeck, J., Goodman, M. H., Moriceau, G., Krijgsman, O., Dharanipragada, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0936 · Cited by 88
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Shen, C., Kim, S. H., Trousil, S., Frederick, D. T., Piris, A., Yuan, P., Cai, L., Gu, L., Li, M., Lee, J. H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4155 · Cited by 96
“%) of BRAFi-resistant melanomas are not driven by any of these known resistance mechanisms 4,5,9 .”
BackgroundResistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 103
“Although BRAF splicing variants are capable of conferring resistance to BRAFi, cell line studies have shown that melanoma cells carrying splicing variant remained susceptible to MEK inhibition [72].”
BackgroundResultInfluentialOkimoto, R. A., Lin, L., Olivas, V., Chan, E., Markegard, E., Rymar, A., Neel, D., Chen, X., Hemmati, G., Bollag, G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610456113 · Cited by 78
Lochovsky, L., Zhang, J., Fu, Y., Khurana, E., & Gerstein, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv803 · Cited by 83
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Queirolo, P., Picasso, V., & Spagnolo, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.010 · Cited by 79
“Nevertheless, BRAF amplifications were also identified in another study on resistant tumours and pre-matched samples derived patients treated with dabrafenib and trametinib in combination, along with MEK1/2 and NRAS mutations [50], and, in addition to alterations of the MAPK pathway, approximately half patients had tu…”
BackgroundResultMEK inhibitors under development for treatment of non-small-cell lung cancer
Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 74
“MEK2), andMEK alterations in the helix A region [91,92].”
BackgroundEvolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer
Thompson, L., Jeusset, L. M., Lepage, C. C., & McManus, K. J. (2017) · Cancers · doi:10.3390/cancers9110151 · Cited by 80
“Indeed, resistance to BRAF/MEK inhibition has been observed in up to one-third of melanoma patients, with genetic analyses revealing most had acquired either activating mutations in additional MAPK pathway members or in compensatory signaling pathways [146,147].”
BackgroundProtein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq
Gerber, T., Willscher, E., Loeffler‐Wirth, H., Hopp, L., Schadendorf, D., Schartl, M., Anderegg, U., Camp, J. G., Treutlein, B., Binder, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13666 · Cited by 80
“However, 50% of patients develop a secondary resistance after 6–9 months [5].”
BackgroundImperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
Locus of control orientation and depressive symptomatology: A meta-analysis.
Presson, P. K., & Benassi, V. A. (1996) · Journal of social behavior and personality · Cited by 96
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 75
Self-citationTumor Heterogeneity and Therapeutic Resistance
Lovly, C. M., Salama, A. K. S., & Salgia, R. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158808 · Cited by 66
Tian, Y., & Guo, W. (2020) · Medical Science Monitor · doi:10.12659/msm.920957 · Cited by 78
Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
Redmer, T. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0854-5 · Cited by 67
“At this point another hurdle commonly appeared: cells developed resistance to MEK inhibitors, and the MAPK pathway was reactivated through an acquisition of MEK activating mutations [147] or BRAF gene amplification [148].”
BackgroundCombination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
Simeone, E., Grimaldi, A. M., Festino, L., Vanella, V., Palla, M., & Ascierto, P. A. (2017) · BioDrugs · doi:10.1007/s40259-016-0208-z · Cited by 71
Váraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 75
“We found that several IL-17-inducing genes were expressed at higher levels in BRAF -mutant than in BRAF -WT tumors in the SKCM cohort and that their expression was significantly decreased in MAPK inhibitor (MAPKi)-treated melanoma tissue biopsies 13–15 (Extended Data Fig.”
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Wei, J., Hu, J., Wang, L., Xie, L., Jin, M. S., Chen, X., Liu, J., & Jin, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01528 · Cited by 66
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 76
“MelBR1 cell line was generated as described previously (38, 39).”
BackgroundMethodWang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
Posch, C., Cholewa, B. D., Vujic, I., Sanlorenzo, M., Ma, J. A., Kim, S. T., Kleffel, S., Schatton, T., Rappersberger, K., Gutteridge, R. E. A., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.198 · Cited by 69
“MAPK reactivation and increased signaling through other pro-survival cascades such as the PI3K/mammalian target of rapamycin (mTOR) and/or cell cycle pathways cause resistance to treatment after only months of therapy (Catalanotti et al. 2013; Long et al. 2014).”
BackgroundAutophagy- An emerging target for melanoma therapy
Ndoye, A., & Weeraratna, A. T. (2016) · F1000Research · doi:10.12688/f1000research.8347.1 · Cited by 78
“Melanoma cells can adopt various mechanisms of resistance such as the re-activation of the mitogen-activated protein kinase (MAPK) signaling pathway 6 and aberrant activation of other signaling pathways such as the insulin-like growth factor receptor (IGFR) and Wnt signaling pathways 7,8 .”
BackgroundMarampon, F., Ciccarelli, C., & ZANI, B. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102530 · Cited by 78
Hong, A., Piva, M., Liu, S., Hugo, W., Lomeli, S. H., Zoete, V., Randolph, C. E., Yang, Z., Wang, Y., Lee, J. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0873 · Cited by 70
Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Perales-Puchalt, A., Nguyen, J. M., Payne, K. K., Singhal, S., Eruslanov, E. B., Tchou, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1308 · Cited by 63
“To extend our observations to the clinical use of trametinib, we analyzed published gene expression data of BRAFV600-mutant melanoma lesions biopsied from patients before and after treatment with trametinib plus dabrafenib (30).”
MethodReddy, S. M., Reuben, A., & Wargo, J. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0531-z · Cited by 63
Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals
Wang, Y., Ou, Z., Sun, Y., Yeh, S., Wang, X., Long, J., & Chang, C. (2016) · Oncogene · doi:10.1038/onc.2016.330 · Cited by 71
Jiang, J., Wang, W., Zheng, H., Chen, X., Liu, X., Xie, Q., Cai, X., Zhang, Z., & Li, R. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121561 · Cited by 60
Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
Anelli, V., Villefranc, J. A., Chhangawala, S., Martinez-McFaline, R., Riva, E., Nguyen, A., Verma, A., Bareja, R., Chen, Z., Scognamiglio, T., et al. (2017) · eLife · doi:10.7554/elife.20728 · Cited by 65
“Clinical studies with these agents in BRAF-mutant melanomas also confirm that combined therapy has greater anti-tumor efficacy in human patients (Long et al., 2014).”
BackgroundResistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R–MEK5–Erk5 Pathway
Benito-Jardón, L., Díaz‐Martínez, M., Arellano‐Sánchez, N., Vaquero-Morales, P., Esparís-Ogando, A., & Teixidó, J. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2762 · Cited by 68
Dabrafenib and its use in the Treatment of Metastatic Melanoma
Bowyer, S. E., Lee, R. J., Fusi, A., & Lorigan, P. C. (2015) · Melanoma Management · doi:10.2217/mmt.15.21 · Cited by 60
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., García‐Rodríguez, J., Ding, M. L., Zaman, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0955 · Cited by 57
“Identified resistance mechanisms include gain-offunction mutations in NRAS (6), MAP2K1 (7, 8), and PIK3CA (9); amplification of COT (10); upregulation of PDGFRβ (6), EGFR (11–13), ERBB3 (14), and IGFR1 (15); and amplification (16) or alternative splice variant expression (17) of BRAF.”
BackgroundSelf-citationTrident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance
Guo, B., Pomicter, A. D., Li, F., Bhatt, S., Chen, C., Li, W., Qi, M., Huang, C., Deininger, M. W., Kong, M. G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107220118 · Cited by 56
Metadata
- Authors
- Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., & Rizos, H.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Rizos, Helen
- ORCID
- Venue
- Nature Communications
- Published
- 2014-12-02
- Volume
- 5
- Issue
- 1
- Pages
- 5694-5694
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2003402062
- Cited by
- 375
- References
- 62
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 44 · 2022: 26 · 2021: 35 · 2020: 36 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 34 · 2015: 24 · 2014: 1
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Westmead Millennium Institute for Medical Research
- Australian Cancer Research Foundation
- Cancer Institute NSW
- Melanoma Institute Australia
- Medical Research Council
- National Health and Medical Research Council (633004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dabrafenib, trametinib, combination therapy resistance, MAPK pathway reactivation, BRAF amplification, NRAS mutation, PI3K signaling, Rac1, AKT3, BRAF V600E mutation, resistance mechanisms
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Imidazoles, Melanoma, Membrane Proteins, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, GTP Phosphohydrolases, rac1 GTP-Binding Protein, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.